Schizophrenia Clinical Trials in Snellville, Georgia

4 studies are recruiting for schizophrenia in Snellville, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. 52-week Open Label Safety-Tolerability Study

    Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Accelerated Clinical Trial, Snellville, Georgia
    Locations
    23 in total
    Run by
    LB Pharmaceuticals Inc.

    See if you can join NCT07369154 on ClinicalTrials.gov

  2. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Accelerated Clinical Trial, Snellville, Georgia
    Locations
    13 in total
    Run by
    LB Pharmaceuticals Inc.

    See if you can join NCT07363577 on ClinicalTrials.gov

  3. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Snellville, Georgia
    Locations
    21 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

  4. Study of ALTO-101 in Patients With Schizophrenia

    This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

    Stage
    Phase 2
    Ages
    21 to 55
    Site
    Site 5064, Snellville, Georgia
    Locations
    14 in total
    Run by
    Alto Neuroscience

    See if you can join NCT06502964 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.